arrow_back Back Filing freshness 10-K FY 2026 SEC EDGAR

HAEMONETICS CORP

HAE
$87.83 ▲ +2.82 (+3.32%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
19 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
66
Health
Good
Bearish
auto_awesome

Analytical Summary

HAEMONETICS CORP faces fundamental challenges with weakness in Debt to Equity. The fundamentals warrant careful consideration of downside risks.

Market Cap $4.1B
Dividend Yield
Revenue Growth -2.0%
Op. Margin 11.7%
ROIC 5.9%
FCF / Share $5.52
Trailing P/E 42.6x
Price / Book 5.0x
FCF Yield 6.3%
Debt / Equity 1.56
info Valuation on last close. End-of-day price, Aug 7, 2026.

19-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.33B
↓ -2.0%
Net Income Profit after all expenses
$97.31M
↓ -42.0%
Operating Margin Operating profit as % of sales
11.7%
↓ -27.9% 73th
FCF / Share Free cash flow per share
$5.52
↑ +95.0%
Long-Term Debt Long-term obligations
$1.24B
↓ -0.5%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)

Health Breakdown

Profitability
71
Returns
67
Financial Health
48
Cash Quality
87

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 19 years · 70 quarters